The Newest Targeted Therapeutics for Thyroid Cancer: Development of Sorafenib and Lenvatinib

Mark Steven Cohen^*

Department of Surgery, Section of General Surgery, Division of Endocrine Surgery University of Michigan Comprehensive Cancer Center, 2920K Taubman Center,1500 East Medical Center Drive, SPC 5331 Ann Arbor, Michigan, USA

^*Corresponding Author: Mark Steven Cohen, Department of Surgery, Section of General Surgery, Division of Endocrine Surgery University of Michigan Comprehensive Cancer Center, 2920K Taubman Center,1500 East Medical Center Drive, SPC 5331 Ann Arbor, Michigan, USA, Tel: 734 - 615-4741 Email: